|Home||» Products||» Oncology Injectionables||» Tocilizumab|
Generic name: Tocilizumab
Drug class and mechanism: Tocilizumab is an injectable synthetic (man-made) protein that binds to interleukin-6 (IL-6) in the body and blocks the effects of IL-6 in patients with rheumatoid arthritis. Inflammation is the body's reaction to injury and is a necessary process for the repair of injury. IL-6 is a protein that the body produces when there is inflammation. IL-6 promotes inflammation and the signs of inflammation, which, in the case of arthritis, includes fever as well as pain, tenderness, and swelling of the joints. The unchecked inflammation of rheumatoid arthritis eventually leads to destruction of the joints. Tocilizumab binds to IL-6 in the body and thereby blocks the effects of IL-6. As a result, inflammation and its consequences in the joints are reduced, and the progressive destruction of the joints is slowed or prevented. The FDA approved tocilizumab in January 2010.
GENERIC AVAILABLE: No
PREPARATIONS: Injection: 20 mg/ml
STORAGE: Tocilizumab should be stored refrigerated at 2 to 8 C (36 to 46 F).